Single dose of H1N1 vaccine produces robust immune response

Preliminary analyses of early data from two vaccine trials in the U.S. show the vaccines to be safe and a single dose produces robust immune response within 8 to 10 days after vaccination

Updated - November 17, 2021 06:53 am IST

Published - September 12, 2009 04:50 pm IST - CHENNAI:

The safety of 2009 influenza A(H1N1) vaccines that are undergoing clinical trials in different countries has got a shot in the arm. Fear about the safety of the vaccines, which are being tested on a fast-track mode, was expressed by some doctors in a few countries.

Much like the findings of the two vaccines that are being tested in the U.K. and Australia, preliminary analyses of early data from two vaccine trials in the U.S. showed the vaccines to be safe and immune responses produced to be good.

The preliminary results of the U.K. and Australia trials were published on September 10 in the New England Journal of Medicine journal.

The Director of The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, U.S. has gone on record saying that the vaccines are safe and produced robust immune response in healthy adults in the 18-64 age group.

Another significant outcome seen in the two trails conducted by NIAID is that a single dose of 15 micrograms was able to produce robust immune responses 8 to 10 days after vaccination. More than 2,800 people are participating in the two ongoing trials.

The Sanofi Pasteur vaccine was able to produce a robust immune response in 96 per cent of adults aged 18 to 64 and in 56 per cent of adults aged 65 and older.

In the case of the CSL Limited vaccine, a robust immune response was measured in 80 per cent of adults aged 18 to 64 and in 60 per cent of adults aged 65 and older.

For adults aged 65 and over, the immune response to 2009 H1N1 influenza vaccine was somewhat less robust, as is the case with seasonal influenza vaccines.

According to an NIAID release, information from their studies will help inform the development of recommendations for immunization schedules, including the optimal dosage and number of doses for different age groups.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.